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Abstract
Chronic liver disease is a major cause of morbidity 
and mortality worldwide and usually develops over 
many years, as a result of chronic inflammation 
and scarring, resulting in end-stage liver disease 
and its complications. The progression of disease is 
characterised by ongoing inflammation and consequent 
fibrosis, although hepatic steatosis is increasingly 
being recognised as an important pathological feature 
of disease, rather than being simply an innocent 
bystander. However, the current gold standard method 
of quantifying and staging liver disease, histological 
analysis by liver biopsy, has several limitations and 
can have associated morbidity and even mortality. 
Therefore, there is a clear need for safe and non-
invasive assessment modalities to determine hepatic 
steatosis, inflammation and fibrosis. This review covers 
key mechanisms and the importance of fibrosis and 
steatosis in the progression of liver disease. We address 
non-invasive imaging and blood biomarker assessments 
that can be used as an alternative to information 
gained on liver biopsy.
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Core tip: Ongoing hepatic fibrosis and steatosis are well 
recognised features of chronic liver disease. Liver biopsy 
is currently the gold standard for assessing the disease 
although this has an associated but low morbidity and 
mortality risk. Therefore, alternative methods of non-
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invasive assessment of liver disease are of relevance 
and importance. We outline the mechanisms of hepatic 
fibrosis and steatosis and review uses of non-invasive 
imaging and blood biomarkers as an alternative to liver 
biopsy.
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CLINICAL PROBLEM
Chronic liver disease is a major cause of morbidity 
and mortality worldwide. The presence of chronic 
inflammation and consequent fibrosis leads to the 
development of cirrhosis and its complications. 
Whilst the exact prevalence of chronic liver disease is 
unknown, cirrhosis of the liver was attributed for more 
than one million deaths worldwide in 2010, although 
these figures probably reflect heavy under-reporting[1]. 
The total worldwide prevalence of cirrhosis has been 
estimated at around 1% with significant regional 
variation owing to the presence of viral hepatitis, the 
metabolic syndrome and alcohol consumption[2].
Chronic liver disease has a varied aetiology, 
including viruses, such as hepatitis B (HBV) and 
hepatitis C (HCV). Worldwide, over half a billion 
people may be chronically infected with either of these 
viruses[3,4]. Metabolic causes include the increasing 
prevalence of non-alcoholic fatty liver disease (NAFLD). 
Toxic causes, such as excess alcohol consumption, 
aflatoxin exposure[5,6] and autoimmune disorders, 
such as primary biliary cirrhosis and autoimmune 
hepatitis, contribute to the disease burden. Over half 
of the deaths attributable to cirrhosis and nearly 80% 
of those attributable to primary liver cancers occur in 
those who have chronic HBV and HCV infection[7], while 
in many developed nations excess alcohol consumption 
is the commonest cause. In the developing world, 
aflatoxin exposure further complicates the picture, 
leading to high rates of hepatocellular carcinoma (HCC). 
Chronic liver disease usually takes many years 
to progress from inflammation, associated with 
hepatocyte injury, to fibrosis and mostly requires long-
term exposure to the causative agent. Progressive 
scarring or fibrosis develops during the period of time 
between initiation and end-stage disease. The resulting 
pre-cirrhotic fibrosis is a target for therapies aimed at 
reducing the rate of progression to cirrhosis, or even 
reversal of fibrosis[8].
Effective antiviral therapies and the advent of 
antifibrotic drugs have led to increasing demand for 
non-invasive, accurate and reliable biomarkers of 
hepatic disease severity. It is well recognised that 
the current “gold standard”, histological analysis of 
liver biopsy, has limitations and engenders risk to 
the patient. Sampling variability and the subjective 
interpretation of scoring systems means that the 
consistency and representation of the true disease 
state is questionable. The procedure frequently causes 
discomfort and if the patient has a malignancy, there 
is a risk of tumour seeding[9]. Furthermore, there 
is frequent associated morbidity and a small, but 
significant, mortality rate[10] in all but a few cases. 
Liver biopsy is rarely performed in lower income 
countries, often due to a lack of expertise to interpret 
results[11]. On the other hand, in the United States and 
the developed world, magnetic resonance techniques 
allow a quantitative assessment of different aspects 
of disease from metabolic markers of inflammation, 
through to assessment of fibrotic load, markers of 
portal hypertension and prognostic indicators of the 
complications of cirrhosis[12]. There is a clear need for 
reliable and effective non-invasive markers of hepatic 
inflammation and fibrosis, both for the management 
of individual patients and for the development of new 
anti-fibrotic therapies. Novel imaging modalities and 
non-invasive biomarkers have the potential to fulfil 
this role and offer significant benefit in treatment 
monitoring and have the potential also to be of use in 
resource-constrained settings.
NATURAL HISTORY OF CHRONIC LIVER 
DISEASE
Chronic liver injury leads to initiation and perpetuation 
of inflammatory processes, which, by a cascade 
of inter-related processes and pathways, leads to 
deposition of fibrous tissue (Figure 1). By convention, 
fibrosis has been considered potentially reversible, 
while the end-stage of the pathological process, 
cirrhosis, has been considered irreversible. However, 
with elimination of the cause of liver injury, a number 
of studies have demonstrated regression of all stages 
of fibrosis in animal models and in humans[13-17]. 
Elucidation of the process of fibrogenesis enables 
markers of disease severity and potential targets for 
therapeutic intervention to be developed. 
KEY MECHANISMS OF FIBROGENESIS
Fibrosis is a dynamic process of hepatic homeostasis 
mediated by several cellular mediators in response to 
an inflammatory process. In particular, hepatic stellate 
cells (HSC) have a central role in the pathogenesis of 
liver fibrosis[8,18]. These cells comprise 15% of liver 
cell mass[19]. HSCs are activated following liver injury 
from a relatively quiescent lipid and vitamin A-storing 
phenotype to a myofibroblastic phenotype, capable of 
proliferation, contraction and fibrogenesis. However, 
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other myofibroblastic cell populations have also been 
shown to be involved in fibrogenesis, including portal 
fibroblasts[20,21] . 
HSC activation occurs in two stages: initiation 
and perpetuation and each involves characteristic 
pathways, as described by Friedman[18]. Initiating 
events may consist of any chronic perturbation of 
hepatic homeostasis, which is often, but not always 
associated with the presence of inflammatory 
cells on liver biopsy. Such perturbations of hepatic 
homeostasis may lead to the net over-production 
of unstable reactive oxygen species (ROS) derived 
from hepatocytes, macrophages, stellate cells and 
inflammatory cells. ROS are potent mediators of 
the initiation and perpetuation of liver injury and 
cause lipid peroxidation of cellular membranes. 
Perpetuation of HSC activation is comprised of a 
number of cellular responses, which lead to increased 
expression and responsiveness to growth factors. 
Perpetuation is a dynamic process, occurring along 
a number of pathways associated with different HSC 
responses. These responses include release of largely 
proinflammatory cytokines, proliferation and increased 
contractility of HSCs, chemotaxis of inflammatory cells 
and the net deposition of pathological ECM[18].
Resolution of fibrosis
For resolution of fibrosis to occur, removal of the 
injurious agent is a prerequisite. Activation of HSCs 
has been shown to be crucial for the development of 
fibrosis, while in recovery and resolution of fibrosis, 
the number of activated HSCs is reduced. The latter 
may occur as a result of reversion to the quiescent 
form or by apoptosis. A return to the quiescent 
form has been observed in vitro[22], but not in vivo. 
Apoptosis has been postulated as the predominant 
mechanism for removal of HSC activity. It has been 
shown that spontaneous apoptosis of HSCs occurs in 
vitro. Conversely, it has also been shown that MMP-2 
levels correlate with apoptosis and may be stimulated 
by apoptosis[23] and that TIMP-1, by inhibition of MMP, 
leads to inhibition of activated HSC apoptosis[24]. 
HEPATIC STEATOSIS
Liver fibrosis is the key pathological feature of pro-
gressive liver disease. However, the accumulation of 
excessive hepatic triglyceride, hepatic steatosis, is 
increasingly recognised as an important factor in the 
pathogenesis of a number of chronic liver diseases, not 
simply an “innocent bystander”.
Definitions
Hepatic steatosis is a pathological lesion, defined 
as the presence of large and small vesicles of fat, 
predominantly triglycerides, accumulating within hepa-
tocytes[25]. Hepatic steatosis is frequently associated 
with obesity, insulin resistance and dyslipidaemia 
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Figure 1  Histology of normal liver, fibrosis and cirrhosis. A: Representative histological images (using Sirius red staining), normal liver; B: Mild to moderate 
fibrosis with portal tract expansion (METAVIR F = 2, Ishak stage 3); C: Moderate “bridging” fibrosis (METAVIR F = 3, Ishak stage 4); D: Cirrhosis (METAVIR F = 4, 
Ishak 5 or 6).
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direct route to hepatic steatosis in HCV infection[29,30].
CURRENT APPROACHES TO THE 
ASSESSMENT OF CHRONIC LIVER 
DISEASE
The evaluation of patients with chronic liver disease 
is largely based on assessment of the clinical history, 
physical examination and measurement of non-specific 
liver enzymes. Most pre-cirrhotic chronic liver disease 
is asymptomatic, where clinical signs are subtle and 
non-specific. Clinical chemistry, so-called “liver function 
tests” (aminotransferases, alkaline phosphatase, 
bilirubin and gamma-glutamyl transferase) and 
haematological indices (cell-counts and the pro-
thrombin time) may be abnormal in cirrhotic and 
pre-cirrhotic disease, but alone, their sensitivity and 
specificity for the diagnosis and staging of chronic liver 
disease is limited[2].
Liver biopsy - the “gold standard” for disease 
assessment
Histological assessment of liver biopsy is the mainstay 
for the diagnosis and staging of chronic liver disease. 
Epidemiological and pathophysiological data support 
fibrosis being the hallmark of chronic liver disease and 
a predictor of outcome[31]. Most liver biopsies for the 
assessment of chronic liver disease are performed 
percutaneously, by passing the biopsy needle between 
the ribs into the right lobe of the liver. Guidelines for 
safe and effective liver biopsy have been published by 
the British Society of Gastroenterology[32].
in those who do not consume excessive quantities 
of alcoholic drinks, where it is termed non-alcoholic 
fatty liver disease[26] (NAFLD). Hepatic steatosis may 
also be a result of secondary causes, which include 
alcoholism, HCV, severe weight loss, total parenteral 
nutrition and drugs (such as amiodarone, diltiazem, 
tamoxifen, steroids and highly active antiretroviral 
therapy)[27]. NAFLD may thus be considered a 
syndrome of various aetiologies, excluding alcohol 
and, by convention, HCV.
Epidemiology
In a systematic review on the epidemiology of NAFLD, 
Vernon and colleagues reported the prevalence of 
NAFLD in the United States ranges from 10%-35% 
in published studies, depending on the investigative 
assessment modality used and the study population[1]. 
Worldwide, NAFLD prevalence ranges from 6%-35% 
with a median of 20%[1].
Key issues in pathophysiology
The development of hepatic steatosis occurs when 
the rate of synthesis or import of fatty acids by 
hepatocytes exceeds the rate of export or catabolism. 
Such an imbalance can occur in a number of ways 
and is summarised in Figure 2 with increased uptake 
of fatty acids by hepatocytes in obesity, increased 
hepatic fatty acid triglyceride synthesis, impaired fatty 
acid mitochondrial β-oxidation and reduced VLDL and 
triglyceride synthesis all being components to consider 
to a greater or lesser extent[28]. Importantly, with 
respect to hepatic triglyceride export, HCV core protein 
has been shown to inhibit this process, providing a 
Insulin resistance
Adipose tissue
Hyperglycaemia/hyperinsulinaemia
↑ De novo  lipogenesis
↑ FFA
↓ β-oxidation
Triglyceride
synthesis
Steatosis
VLDL
Excess dietary lipids
Figure 2  Summary of metabolic mechanisms leading to hepatic steatosis. Reproduced from Dowman et al[155] with permission from Oxford University Press.
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Validity of histological scoring systems
Fibrosis and inflammation: The interpretation of the 
histology of liver tissue in chronic liver diseases is based 
on categorisation or scoring of inflammatory features 
(grade) and fibrosis and architectural disruption 
(stage)[33]. The first major scoring system was developed 
in 1981, and based on the identification of periportal 
necrosis, intralobular necrosis, portal inflammation and 
fibrosis, assessed separately and assigned a score[34], 
although it was later modified to include additional 
components[35]. The first three components of the 
score contribute to the necroinflammatory grade, while 
the fibrosis score, from 0-6, is based on architectural 
changes in the pattern and expansion of fibrous bands. 
From a practical perspective, cirrhosis is represented 
by both stage 5 (incomplete cirrhosis) and 6 (probable 
or definite cirrhosis).
The METAVIR scoring system was developed 
to look specifically at HCV-related liver disease. 
The histological activity is based on piecemeal and 
lobular necrosis, while the fibrosis stage is scored 
from 0-4, with 4 representing cirrhosis[36]. All scoring 
systems are designed to place a numeric value to 
architectural features. They consist of ordered categorical 
data representing qualitative and semi-quantitative 
descriptions, so are not quantitative measures of fibrosis. 
Studies of liver tissue using digital image analysis have 
shown that the area of fibrous tissue is not linearly 
related to the fibrosis score. Moreover, inflammation 
may cause expansion of fibrous tracts[33]. Nevertheless, 
histological fibrosis assessment has been validated 
by successive clinical studies, making the features 
clinically relevant[31].
Steatosis: Scoring systems quantify fat on the basis 
of visible hepatic lipid droplets within hepatocytes. 
The grade of steatosis is based on the proportion of 
hepatocytes containing visible lipid and is expressed 
semi-quantitatively on a scale of 0-3 (0, < 5%; 1, 
5%-33%; 2, > 33%-66%; 3, > 66%)[37,38]. Grading 
is considered in the context of other histopathological 
lesions, such as inflammatory infiltration and ballooning 
of hepatocytes. However, there are considerable 
limitations to liver biopsy for the quantification of 
hepatic lipid. Quantification of lipid is based only 
on visible lipid droplets, so invisible (for example, 
membrane) lipid is not included. The assessment 
is only semi-quantitative, being a two-dimensional 
estimation of the proportion of hepatocytes including 
lipid, and not considering the volume of droplets. 
Finally, the composition of the fatty acid components 
is not assessed, although, using immunohistochemical 
techniques, the presence of lipid peroxidation products 
may be determined[39].
Limitations of liver biopsy
Morbidity and mortality: Percutaneous liver biopsy 
has a small, but quantifiable, risk of mortality, quoted 
as between 1 in 1000 and 1 in 10000 patients[10,40,41]. 
Minor complications, such as post-procedural pain 
or localised haematoma, occur in between 3% and 
30% of cases. More severe complications, including 
intraperitoneal haemorrhage (requiring transfusion) 
or perforation of a viscus (including pneumothorax) 
may occur in 0.3% to 0.6% of cases[32,42]. Tumour 
seeding following biopsy of suspected carcinomas in 
cirrhosis may also occur in 2.7% of cases[43]. Good 
management of clotting disorders and the appropriate 
use of the transjugular approach for liver biopsy may 
improve outcome[32].
Sampling variability: Percutaneous liver biopsy 
typically samples less than 1/50000th of the liver, 
so any heterogeneity of pathological features may 
lead to sampling variability[44]. Autopsy studies have 
demonstrated that cirrhosis may be missed on a 
single pass liver biopsy in between 10% and 30% of 
cases[45,46], while a study using laparoscopic biopsy of 
both left and right lobes of the liver found a difference 
of at least one fibrosis stage between lobes in over 
30% of patients[47]. The size of the liver biopsy 
specimen influences sampling variability. Smaller 
biopsy sizes (in length and breadth) were shown to 
lead to a lower probability of observing characteristics 
of more severe diseases and, consequently, led to 
underestimation of disease severity[48]. 
Subjectivity and inter-observer variation: 
Histological scoring systems are designed to be 
objective and reproducible, but interpretation is still 
a source of error. Inter-observer variability is low 
for the assessment of fibrosis, but higher for the 
assessment of activity or inflammation[49]. In a study 
of intra- and inter-observer variability, agreement 
was better for fibrosis than inflammation and also 
amongst experienced pathologists than more junior 
pathologists[50]. These authors concluded that the 
experience of the pathologist had more influence on 
agreement than the characteristics of the biopsy itself. 
Histology of liver biopsy specimens is still the mainstay 
for the definitive diagnosis of liver diseases and for 
investigation of co-existing pathology. Nevertheless, 
there are risks inherent in the technique and scoring 
systems should be interpreted in the knowledge of the 
limitations.
NON-INVASIVE TECHNIQUES
Non-invasive assessment techniques are suited to 
longitudinal studies as the risk to patients is more 
limited than liver biopsy. However, the measured 
parameters may be more susceptible to influence by 
confounding factors and so specificity is important to 
consider. Non-invasive tests of chronic liver disease 
may be broadly divided into serum (or blood) markers 
and imaging-based technologies. 
Karanjia RN et al . Hepatic steatosis and fibrosis
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Serum markers
Serum markers have been studied in detail to detect 
early fibrotic changes as blood tests are quick and 
acceptable to patients. While the results are objective, 
there is the possibility of the presence of confounding 
factors from extrahepatic disease. These have been 
reviewed extensively[51-53]. Serum markers may bro-
adly be divided into “indirect” and “direct” markers, 
single tests and panels. Indirect markers are markers 
of liver function, which reflect liver fibrosis, while 
direct markers include serum extracellular matrix 
components and intermediates of fibrogenesis[54]. 
The strengths and limitations of the most widely used 
models are summarized below.
APRI
APRI (AST to Platelet Ratio Index) was proposed as 
an alternative to biopsy in patients with chronic HCV 
infection[55] and it is calculated as (AST/upper limit of 
normal range)/platelet count (109/L) × 100. A recent 
meta-analysis by Lin and colleagues showed APRI 
had AUROC scores for the diagnosis of significant 
fibrosis, severe fibrosis, and cirrhosis of 0.77, 0.80, 
and 0.83 respectively, demonstrating a potential use 
for identifying HCV-related fibrosis[56]. However, APRI 
fails to identify a significant proportion of people in the 
earlier stages of fibrosis and therefore is limited in its 
ability to identify only significant and untreated chronic 
HCV-related fibrosis[55,57].
Enhanced liver fibrosis score
The enhanced liver fibrosis score (ELF®) score 
(Siemens, Munich, Germany) combines three direct 
markers of fibrosis including hyaluronic acid (a 
component of the extracellular matrix), TIMP-1 (an 
inhibitor of matrix metalloproteinases, which break 
down collagen) and PIINP (a marker of collagen 
synthesis at disease site). Therefore, the premise of 
this scoring system is that a higher score will indicate 
a higher rate of fibrogenesis. ELF® has been shown to 
have good performance for the detection of significant 
fibrosis in chronic HCV (93% sensitivity and 83% 
specificity)[58] but also in NAFLD (sensitivity 89% and 
specificity 96%) and ALD (100% sensitivity and 16.7% 
specificity)[59], although results for the latter two have 
been less rigorously evaluated. Results also need to be 
adjusted appropriately as scores can be influenced by 
gender, age, and sex[60].
FibroTest®
FibroTest® (BioPredictive, Paris, France) uses five 
different serum markers in its model and has been 
validated in meta-analysis in multiple aetiologies 
including NAFLD (AUROC 0.84; 95%CI: 0.76-0.92), 
alcohol-related liver disease (AUROC 0.86; 95%CI: 
0.80-0.92) and both chronic HBV infection (AUROC 
0.80; 95%CI: 0.77-0.84) and HCV infection (AUROC 
0.85; 95%CI: 0.82-0.87)[61]. However, results are 
limited by false-positive results, attributed to increases 
in bilirubin or decreases in haptoglobin; in particular 
HCV patients on ribavirin. Results can also be affected 
by acute inflammation, Gilbert’s syndrome and 
cholestasis[52]. 
FIB-4 index: The FIB-4 index combines several 
markers of liver function into the following formula: 
age (years) × AST [U/L]/(platelets [109/L] × (ALT 
[U/L]). The FIB-4 index was specifically developed 
as an alternative to biopsy in patients with chronic 
HCV infection, although it has shown use in other 
causes of liver disease. In a study of 529 HCV-
infected patients, the FIB-4 index enabled the correct 
identification of patients with severe fibrosis (F3-F4) 
and cirrhosis with an Area under Receiver Operated 
Curve (AUROC) of 0.85 (95%CI: 0.82-0.89) and 0.91 
(95%CI: 0.86-0.93), respectively[62]. However, a lack 
of universal agreement amongst studies for positive 
and negative cut-off values has proved problematic.
Forns index: The Forns index is another formula that 
assesses liver function by combining age, cholesterol, 
gamma-glutamyltranspeptidase and platelet count. 
Forns and colleagues showed using a best cut-off 
score of < 4.2, the presence of significant fibrosis 
(F2-F4) could be excluded with high accuracy (negative 
predictive value of 96%) in 125 (36%) of 351 patients 
with chronic HCV infection[63]. The Forns index has also 
been shown to be more accurate than other serum 
markers including FIB-4 and aspartate APRI (AUROC 
0.795, 0.764 and 0.774 respectively) in the prediction 
of significant fibrosis in patients with chronic HCV[64].
IMAGING-BASED MODALITIES AS 
ALTERNATIVES TO BIOPSY
Various imaging modalities have been proposed as 
alternatives to liver biopsy. Given that there is strong 
evidence that liver stiffness measurements (LSM) 
increases with the degree of fibrosis[65,66], the most 
successful imaging modalities have used techniques 
to measure liver stiffness and correlate this with the 
degree of fibrosis, most notably ultrasound-based 
transient elastography (TE) and acoustic radiation 
force impulse imaging (ARFI®, Siemens, Munich, 
Germany). Their potential use in the measurement 
of hepatic steatosis and differentiation of hepatic 
steatosis grade has also been investigated. The use of 
other modalities, including MR techniques, to assess 
morphological and biochemical changes in chronic liver 
disease (CLD) will also be discussed. 
Transient elastography
Transient elastography (TE) was first developed as 
Fibroscan® (Echosens, Paris, France), where a vibrator 
generates low frequency shear waves through the 
liver which are then transmitted to an ultrasound 
Karanjia RN et al . Hepatic steatosis and fibrosis
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receiver. The velocity of the waves is dependent on the 
tissue elasticity and therefore, the rate of propagation 
through the liver can be used as a measure of liver 
stiffness and converted into a numerical value (kPa). 
Meta-analyses have shown TE has a very high sensitivity 
and specificity for detecting cirrhosis, but its accuracy 
was much reduced in the earlier stages of fibrosis[67,68]. 
This is partly due to the lack of validation for stiffness 
cut-off values in earlier stages of disease, but also 
possibly due to the multiple processes that contribute 
to liver stiffness other than fibrosis[67,69]. Fibroscan® 
machines now have been calibrated to measure hepatic 
steatosis levels by using a novel Controlled Attenuation 
Parameter (CAP®; Echosens, Paris, France), with results 
showing a sensitivity and specificity between 78% and 
100% and an excellent correlation between different 
steatosis grades, determined by the percentage of 
hepatocytes with fatty infiltration (Spearman Rank 
ρ = 0.81, P < 10-16)[70]. Its use has been validated in 
patients with chronic hepatitis C infection (AUROC 
0.80; 95%CI: (0.75-0.84) for S ≥ 1, 0.86; 95%CI: 
0.81-0.92 for S ≥ 2 and 0.88; 95%CI: 0.73-1.00 for S 
= 3) respectively and has shown correlation in patients 
withNAFLD (0.49, P = 0.00069) although this accuracy 
reduces with increasing steatosis grade in patients with 
NAFLD[71,72].
ARFI®
Acoustic radiation force impulse imaging (ARFI)® 
(Siemens, Munich, Germany) is another form of ultra-
sound elastography that measures soft tissue dis-
placement following the exposure of high-energy 
acoustic pulses. The measurement of displacement can 
then be quantified and interpreted as a measurement 
of liver stiffness. Meta-analysis by Friedrich-Rust and 
colleagues used AUROC to show ARFI® is effective with 
scores of 0.87 for discriminating significant fibrosis, 
0.91 for severe fibrosis and 0.93 for cirrhosis[73]. 
Additionally, ARFI® has also shown comparable results 
with TE for detection of significant fibrosis and cirrhosis 
and was significantly more likely to obtain reliable 
measurements[74]. However, its uses for detecting 
earlier stages of fibrosis though remain limited.
ElastPQ® 
ElastPQ® (Philips, Best, Netherlands) is a newer 
ultrasound method of non-invasive assessment of 
liver stiffness and uses two-dimensional shear wave 
elastography to generate an absolute measurement of 
liver stiffness. ElastPQ® showed comparable accuracy 
to ARFI® when differentiating 176 patients with and 
without chronic liver disease (83.7% vs 83.1%), al-
though measurements of liver stiffness for ElastPQ® 
were significantly lower, compared to ARFI® and thus 
required different cut-off values[75]. Additionally, in a 
study of 291 patients with chronic HBV, who under-
went biopsy or partial hepatectomy, ElastPQ® values 
showed good correlation between the stage of liver 
fibrosis and grade of necroinflammatory activity while 
being unaffected by levels of steatosis[76]. However, 
whilst ElastPQ® remains an exciting prospect, further 
comparisons with other non-invasive imaging moda-
lities and liver biopsy are needed.
Standard ultrasound
Ultrasound is widely used clinically to detect hepatic 
steatosis, but it can also detect the vascular changes 
of chronic liver disease with contrast enhancement[77]. 
Ultrasound is also able to detects hepatic steatosis, 
based on the premise that steatosis causes increased 
echogenicity of the hepatic parenchyma, leading 
to a brighter image when compared to the cortex 
of the ipsilateral kidney[78]. Other conditions, such 
as fibrosis may also lead to increased echogenicity, 
resulting in a potential for confusion. A review of the 
non-invasive measurement of fat content found the 
sensitivity of ultrasound for the detection of steatosis 
to range from 60% to 94%, while the specificity 
ranged from 84% to 95%[79]. However, histologically-
assessed mild steatosis resulted in a sensitivity of just 
55%[80]. In addition, obesity reduces the accuracy of 
ultrasound due to technical considerations and increased 
attenuation of signal caused by subcutaneous fat. 
Ultrasound performs more poorly for the quantification 
of hepatic lipid, although subjective grading systems, 
categorizing steatosis into mild, moderate and severe 
groups have been proposed[81]. Dynamic microbubble 
contrast-enhanced studies are thought to exploit the 
intra- and extrahepatic vascular changes that generate 
shortening of hepatic vein transit times with increasing 
disease severity[82,83] (Figure 3). 
Computed tomography
CT enables the assessment of hepatic steatosis on the 
basis of radiographic density[84], although the ability to 
quantify hepatic lipid is not clear[85]. Ionising radiation 
associated with CT-scanning confers a small excess 
risk to subjects, making it less suited for repeated 
measurements.
Magnetic resonance imaging
T1 and T2 mapping are MR techniques that can be used 
for in vivo tissue characterisation either individually 
or in combination. T1 relaxation times correlate with 
increased levels of extracellular fluid associated 
with inflammation and fibrosis, whereas T2 mapping 
primarily reflects the amount of iron deposition[86]. 
For example, T1 mapping of the liver has used a 
modified Look-Locker inversion recovery sequence 
with motion recovery[87] and T2 on multi-gradient-echo 
acquisition[88]. Since elevated iron levels interfere with 
T1 measurements, correction algorithms are applied 
to provide more accurate readings[86]. T1 mapping has 
shown good correlation with the histological degree 
of fibrosis in a cohort of 79 patients with chronic liver 
disease of multiple aetiologies with a ROC of 0.94 for 
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any degree of fibrosis[88]. 
Additionally, Pavlides and colleagues have used 
T1 mapping to show a correlation with the degree 
of liver disease and the risk for developing clinical 
events in 112 patients. Optimal T1 cut-off points were 
created by comparing multiparametric MR data with 
histological staging of fibrosis from previous studies. 
This was used to create a “liver inflammation and 
fibrosis” (LIF) staging score. Pavlides subsequently 
found that patients with severe liver disease (LIF > 
3) were at higher risk for developing clinical events, 
compared to patients with LIF <1 (P = 0.02) and 
LIF 1-1.99 (P = 0.03)[86]. T1 mapping has also been 
shown to differentiate Child-Pugh A patients from 
Child-Pugh B/C patients effectively (P < 0.00001)[89]. 
T1 mapping is a promising diagnostic tool that has 
shown to be effective in differentiating different stages 
of fibrosis and also has shown potential for predicting 
clinical events. However, further research is needed to 
validate effective scoring systems and the influences 
of other compounding factors for it to become a valid 
alternative to liver biopsy in clinical practice. 
Magnetic resonance elastography 
While ultrasound-based transient elastography tech-
niques such as Fibroscan® measure liver stiffness in 
a defined region (about 5cm3, right lobe of the liver), 
Magnetic Resonance Elastography (MRE) can be used 
to predict fibrosis stage effectively in patients with 
chronic liver disease, while producing a wider and more 
representative map of liver stiffness in both 2D and 
3D planes. This is performed using similar principles to 
TE, whereby propagating shear waves are generated 
and imaged using phase contrast MRI, which includes 
oscillating motion sensitising gradients (MSGs). The 
subsequent cyclic spin displacement of protons, which 
in the presence of synchronised MSGs, are encoded as 
phase shifts within the MRI signal[90].
MRE has been validated in multiple studies and 
meta-analyses[91-94]. One meta-analysis by Singh and 
colleagues using 12 retrospective studies, comprising 
697 patients with CLD of varying aetiology, showed 
MRE had high diagnostic capability for detecting 
significant fibrosis (F ≥ 2), advanced fibrosis (F ≥ 3), 
as well as cirrhosis with ROC values of 0.88 (0.84-0.91), 
0.93 (0.90-0.95), and 0.92 (0.90-0.94) respectively, 
as determined by liver biopsy[91]. Another meta-
analysis by Su and colleagues, comprising 13 studies 
and 989 patients, also demonstrated good sensitivity 
and specificity of MRE for the staging of fibrosis. The 
pooled sensitivity and specificity for F ≥ 1, F ≥ 2, F ≥ 
3 and F = 4 were 0.87 (95%CI: 0.84-0.89) and 0.92 
(95%CI: 0.87-0.96), 0.87 (95%CI: 0.84-0.90) and 
0.92 (95%CI: 0.89-0.95), 0.88 (95%CI: 0.85-0.91) 
and 0.91 (95%CI: 0.88-0.93), 0.91 (95%CI: 
0.87-0.94) and 0.92 (95%CI: 0.89-0.94), respectively. 
The pooled ROC values for F ≥ 1, F ≥ 2, F ≥ 3 and 
F = 4 were 0.9502, 0.9663, 0.9644, and 0.9768, 
respectively[92]. MRE can also be used to stratify risk 
of cirrhosis progression in patients with chronic HCV 
infection[95] and may have greater potential than TE 
for assessment of NAFLD in patients with high risk of 
NASH or cirrhosis, due to the multiparametric nature 
of MRI which allows for a comprehensive assessment 
of the liver[96]. 
Recent studies have shown that three-dimensional 
spin-echo echoplanar imaging (3D-SE-EPI) could have 
better diagnostic accuracy than conventional two-
dimensional gradient-recalled echo (2D-GRE). In a 
study of 179 patients with either chronic HBV or HCV 
infection, Shi and colleagues showed AUCs for the 
characterisation of F ≥ 1, F ≥ 2, F ≥ 3, and F = 4 were 
0.957 (95%CI: 0.913-0.983), 0.971 (0.932-0.991), 
0.991 (0.961-0.999), and 0.979 (0.942-0.995) for 
3D-SE-EPI compared with the AUCs for 2D-GRE at 
each fibrosis stage which were 0.948 (0.901-0.977), 
0.959 (0.915-0.981), 0.979 (0.943-0.995), and 0.976 
(0.938-0.994) respectively[97]. A higher diagnostic 
accuracy for 3D-SE-EPI compared with 2D-GRE has 
also been shown for patients with NAFLD advanced 
fibrosis[98]. 
Proton magnetic resonance spectroscopy
Since a Magnetic Resonance Spectroscopy (1H MRS) 
spectrum of the liver is dominated by lipid and water 
resonances, 1H MRS has been used for the assessment 
of hepatic fat. The percentage liver fat has been 
estimated from the number of protons in the lipid 
and water resonances by calibration with hepatic lipid 
extracts[99]. Such measures have been used to assess 
racial differences in the prevalence of hepatic steatosis 
and the technique has also been applied in a population 
of over 2000 participants[100,101]. Simpler lipid-to-water 
resonance ratios have been used to compare hepatic 
steatosis between obese and lean individuals and have 
demonstrated a change in intrahepatic lipid in response 
to dietary intervention[102-104]. 1H MRS also has also 
been applied to the assessment of steatosis in living-
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Figure 3  Hepatic vascular transit times in normal patients and patients 
with cirrhosis. Time intensity curves from the hepatic vein show earlier arrival 
of contrast in the cirrhotic liver[83].
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donor liver transplantation[105] and for quantification of 
steatosis in HIV mono-infected individuals who are at 
greater risk of liver fibrosis and cirrhosis[106].
Proton density fat fraction
MRI techniques can also be used to calculate the 
proton density fat fraction (PDFF), a marker of 
hepatic steatosis, using MRS as a reference. PDFF is 
defined as the ratio of density of mobile protons from 
triglycerides and the total density of protons from 
mobile triglycerides and mobile water which then 
reflects the concentration of fat within that tissue 
in the absence of confounding factors[107]. PDFF has 
shown at least equivalence in accuracy for quantifying 
hepatic steatosis with both 1H MRS and with his-
tological grade, across several studies with various 
aetiologies of chronic liver disease[108-112]. Additionally, 
in a retrospective study of data from 506 adults, PDFF 
estimation accuracy was not affected by age, sex and 
BMI with the authors concluding these confounders 
have a clinically negligible effect[113]. Further validation 
of these techniques would be of benefit as 1H MRS 
techniques are not widely available.
Phosphorus MRS
Phosphorus (31P) MRS currently remains a research tool 
and allows observation of metabolites associated with 
energy metabolism as well as membrane phospholipid 
turnover. The latter include phosphomonoesters 
(PME), thought broadly to represent membrane 
precursors including phosphoethanolamine, 
phosphocholine and phosphodiesters (PDE), which 
are thought to represent membrane degradation 
products including glycerophosphocholine and 
glycerophosphoethanolamine. Studies in chronic liver 
disease both in vitro[114,115] and in vivo[116,117] have 
demonstrated a correlation between the PME/PDE 
and disease state or severity (Figure 4). A study in 
patients with acute hepatitis A demonstrated an acute 
rise in PME/PDE, which decreased with resolution of 
disease[118]. Moreover, in patients with hepatitis C, 
the PME/PDE decreased significantly in those respon-
ding to antiviral treatment but did not change in non-
responders[119].
Combination techniques
Combinations of non-invasive techniques can be used 
to improve accuracy. Serum biomarker models can 
be combined to create more accurate algorithms, 
such as the Fibropaca algorithm, Leroy algorithm 
and SAFE biopsy, with some studies suggesting their 
use could reduce the number of liver biopsies by 
79%[120]. However, the use of serum biomarkers in 
combination with imaging techniques has proved 
highly useful. One study of 183 patients with chronic 
HCV by Castera and colleagues demonstrated that a 
combination of serum FibroTest® and ultrasound-based 
Fibroscan® (TE) (the Bordeaux algorithm) showed an 
increased AUROC score for F2 (0.88 vs 0.83) and F3 
(0.95 vs 0.90), compared to Fibroscan® alone, thus 
avoiding the need for biopsy in a large proportion 
of patients[121]. The Anger’s algorithm combines the 
serum biomarker model, Fibrometer® (Echosens, 
Paris, France) and ultrasound-based Fibroscan®. TE 
has also demonstrated good diagnostic accuracy and 
required significantly fewer biopsies than the Bordeaux 
algorithm for significant fibrosis (20.2% vs 28.6%, P 
= 0.02) and cirrhosis (9.3% vs 25.3%, P = 10-3)[122]. 
Most recently, the role of combination techniques as 
a cost-effective screening tool has been validated 
by Harman and colleagues in a community setting 
in Nottingham, United Kingdom (practice population 
10479). High-risk patients were identified using risk 
factors for chronic liver disease and subsequently 
investigated them using a serial biomarker algorithm 
and liver stiffness measurement (Figure 5). Of the 504 
identified as being high risk, 62 patients (12.3%) had 
normal biomarkers and were not further investigated. 
378 patients then agreed to undergo TE which found 
98 patients (26.8% of valid scans) had clinically 
significant fibrosis (defined as LSM < 8kPa). Most 
interestingly, 71/98 patients (72.4%) of these patients 
had normal liver enzymes and would have been 
otherwise missed by conventional algorithm models. 
This techniques also managed to identify 140% more 
patients with definite cirrhosis (n = 11)[123].
IMAGING MODALITIES TO DETECT 
FEATURES OF CLD
Imaging modalities are can be used to detect a 
number of signs or physical parameters, which are of 
relevance to chronic liver disease. 
Morphological changes
The later stages of chronic liver disease are cha-
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Figure 4  31P magnetic resonance spectroscopy of patients with 
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racterised by a number of intra- and extrahepatic 
structural changes. A number of these structural 
changes are manifestations or consequences of 
other pathological processes. The cirrhotic liver is 
typically small with an uneven border or perimeter. 
These features are caused by the contraction of thick 
bands of fibrous tissue interspersed by regenerative 
nodules. Ultrasound-visible features, such as liver 
surface nodularity, caudate lobe hypertrophy and the 
presence of detectable hepatic venous blood flow 
have been shown to identify those with severe fibrosis 
or cirrhosis from a cohort of patients with chronic 
liver disease, although it is doubtful that the severe 
fibrosis group alone would be identifiable by such a 
technique[124]. Routine MRI, computed tomography (CT) 
and ultrasound indices can detect gross morphological 
changes associated with cirrhosis, but none is sensitive 
or specific. Moreover, pre-cirrhotic disease is not 
adequately discriminated[125-127]. However, dynamic 
superparamagnetic iron oxide (SPIO)-enhanced and 
gadolinium-enhanced MRI demonstrates reticular-
nodular patterns, thought to represent septal hepatic 
fibrosis, the presence of which, taken with an overall 
(subjective) qualitative assessment, allows the 
discrimination of moderate and severe from mild 
fibrosis[128] (Figure 6). Digital image processing of 
unenhanced CT scans has enabled assessment 
of the distribution of high-attenuation patterning, 
again presumed to represent fibrosis and distinction 
between moderate and severe fibrosis[129]. However, 
these techniques do not provide a quantitative 
measure of disease severity, and a number of the 
techniques remain unvalidated by other centres. 
Water molecules are tightly bound in the fibrotic 
extracellular matrix, providing the rationale behind 
the application of diffusion-weighted MR imaging 
(DWI) to chronic liver disease. An apparent diffusion 
coefficient (ADC) is derived, representing proton, and 
hence water, mobility. A reduced ADC is observed 
in cirrhosis and with increasing fibrosis stage, and 
has been interpreted as being due to restriction of 
water diffusion in fibrotic tissue[130,131], or possibly by 
reduced capillary perfusion[132]. However, the precise 
relationship between the ADC and fibrosis is currently 
unclear.
Portal hypertension
Portal hypertension is the cause of much morbidity and 
mortality associated with chronic liver disease, through 
development of varices of porto-systemic anastomoses 
and through activation of vasodilatory pathways 
and development of ascites and the hepatorenal 
Figure 5  Diagnostic algorithm and patient flow chart of the non-invasive biomarker and TE pathway
[123]
. ALT: Alanine aminotransferase; AST: Aspartate 
aminotransferase; GP: General practitioner; TE: Transient elastography.
Step 1: Identification of risk
1027 patients
920 patients eligible for study
Step 2: Simple blood-based
biomarker
504 patients
Step 3: Transient elastography
378 underwent TE
Step 4: Hepatology clinic
98 patients with elevated liver
stiffness (≥ 8 kilopascals)
Lifestyle advice and GP 
follow-up
268 patients with normal liver 
stiffness (< 8 kilopascals)
12 patients without valid TE
62 normal blood - based biomarker
60 refused scan
17 did not attend scan
Exclusions
71 severe comorbidity
22 died or left practice prior to study
8 known chronic liver disease
6 contraindication (e.g. , pacemaker)
13 patients raised
ALT and AST:ALT ratio
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syndrome. Increased portal pressure is caused 
by increased intrahepatic resistance to flow which 
results from both vascular factors and fibrosis[133]. 
The structural results of portal hypertension, such as 
splenomegaly, ascites and the presence of venous 
collaterals are also readily assessed by conventional 
imaging techniques, but these features tend to be 
associated with decompensated cirrhosis and not pre-
cirrhotic disease stages. A number of ultrasound-
based studies have aimed to assess portal pressure 
indirectly as a surrogate for disease severity[134]. 
However, ultrasound Doppler indices of portal flow 
were found not to correlate reliably with increasing 
severity of disease[135,136]. A number of studies have 
pointed to a relationship between portal hypertension 
and liver stiffness measurement (LSM) measured by 
Fibroscan®. Foucher and colleagues demonstrated a 
correlation between liver stiffness measurement and 
splenomegaly, the presence of oesophageal varices 
and a history of bleeding varices[137]. A relationship 
between LSM, measured by Fibroscan® and the 
presence of varices has also been described, although 
evidence for the relationship between LSM and size 
of varices is mixed[138,139]. Vizzutti and colleagues 
went on to demonstrate correlation between LSM 
and the hepatic venous pressure gradient (HVPG), 
particularly at lower HVPG values (< 10-12 mmHg). 
This represents a complex relationship, which was 
less apparent at higher HVPG values[139]. It has 
been stated that the “progressive rise in portal 
pressure...[is]…due mainly to an increase in intrahepatic 
vascular resistance from the accumulation of fibrillar 
extracellular matrix”[140]. However, increased arterial 
and portal inflow may contribute directly to the liver 
stiffness, while haemodynamic changes characteristic of 
advanced portal hypertension, including extrahepatic 
haemodynamic changes, may not be detected by 
changes in liver stiffness.
Intrahepatic vascular changes
Vascular remodeling is increasingly seen as a patho-
logical feature of chronic liver disease. In the deve-
lopment of fibrosis, obliteration of the small hepatic 
and portal veins may lead to a congestive hepatopathy, 
which is exacerbated by a co-existent hyperdynamic 
circulation[141]. This results in inflammation and oxidative 
stress, both triggers for fibrogenesis. Intrahepatic 
vascular remodeling within the fibrotic liver is performed 
by the contractile HSCs, mediated by changes in levels 
of nitric oxide (NO), consequent to derangement of 
endothelial NO synthase. This contributes to high 
resistance and constricted sinusoidal vessels[142]. Such 
mechanisms may also contribute to the development of 
intrahepatic vascular shunts. Imaging techniques assess 
changes in physical properties consequent to vascular 
alteration. While vascular changes occur with increasing 
fibrosis, imaging techniques do not assess fibrosis 
directly, so may be considered surrogate markers in this 
context. 
Inflammation and cell turnover
Hepatic inflammation is associated with cellular inflam-
matory infiltrate, tissue oedema and hepatocyte 
swelling. Each of these is likely to affect the physical 
properties of liver tissue and, as such, can be 
measured by imaging modalities. These properties 
include: nuclear relaxation (T2), assessed by MR 
techniques; water perfusion and diffusion, as assessed 
by DWI; liver stiffness; changes in attenuation, 
assessed by CT and echogenicity, assessed by B-mode 
ultrasound.
Liver stiffness 
The association between liver stiffness on Fibroscan® and 
disease activity, or necroinflammatory score on his-
tology has been shown by a step-wise increase of 
liver stiffness measurements (LSM) with necroinflam-
matory activity in a cohort of patients with disease of 
varied aetiology[143]. The relationship between LSM 
and biochemical activity in patients with chronic viral he-
patitis has also been studied using Fibroscan®. The LSM 
was lower, stage-for-stage, in those with biochemical 
Figure 6  Transverse MR images of cirrhotic liver in vivo[128]. A: SPIO-enhanced two-dimensional spoiled gradient echo (SPGR) image with echotime of 2.65 ms; 
B: Double-enhanced SPGR image at the same level, showing hyperintense reticulations and hypointense nodules (arrows), thought to represent fibrous septal bands 
surrounding regenerative nodules.
A B
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remission (assessed by ALT) than those with a higher 
ALT[144]. Studies have specifically addressed the effect 
of hepatic inflammation on LSM. In one, 18 patients 
without a past history of liver disease, but with acute 
viral hepatitis, were studied. The LSM on Fibroscan® at 
the peak aminotransferase level exceeded 12kPa (the 
cut-off for prediction of cirrhosis) and furthermore, in 
all but one subject, the LSM returned to within normal 
range (below 7kPa). In addition, the LSM correlated 
with the aminotransferases at onset and with the 
AST at follow-up[145]. In another Fibroscan® paper, 
20 patients with acute hepatitis of varying aetiology 
were studied. In those followed up longitudinally, the 
aminotransferases returned to a level commensurate 
with the fibrosis stage at biopsy[146]. While it is known 
that acute hepatitis is associated with an inflammatory 
infiltrate, tissue oedema and hepatocyte swelling, 
(all of which are likely to affect LSM), there was no 
histological confirmation of these features in these 
studies, as liver biopsy was not clinically indicated[147].
The development of ultrasound-based TE has 
enabled the rapid acquisition of objective liver stiff-
ness measurements in vivo[65]. Multiple regression 
analysis in early studies demonstrated a relationship 
between elasticity measurements and fibrosis stage, 
but not to the histologically-measured disease 
activity, necroinflammatory score or the degree of 
steatosis[65,66]. A number of studies have confirmed the 
correlation between liver stiffness and hepatic fibrosis 
in chronic HCV infection[66,148], and other chronic 
hepatic conditions[149-151] with meta-analyses and 
systematic reviews also being recently published[68,152]. 
However, studies have also indicated the presence 
of co-existing factors that may contribute to liver 
stiffness, including inflammation, portal hypertension 
and possibly steatosis[137,147,150,151]. It has also been 
stressed that “biological tissue is a composite material 
and it is difficult to separate the influence of each 
component of the tissue on the total in modulus esti-
mates”[153]. Substantial differences in cut-off values for 
cirrhosis have been observed on Fibroscan® between 
those with chronic hepatitis and those with alcohol-
related chronic liver disease and NAFLD, perhaps 
representing modification of liver stiffness by coexisting 
fat[150,151,154]. Thus, there is circumstantial evidence that 
steatosis affects liver stiffness although the magnitude 
of the effect is likely to be smaller than that of other 
contributing factors, such as fibrosis, inflammation and 
portal hypertension. 
Summary
The development of chronic liver disease is a major 
cause of morbidity and mortality worldwide and 
usually occurs over many years from progressive 
fibrosis and associated hepatocellular injury, including 
steatosis. Non-invasive assessments using imaging 
modalities and serum markers have now been shown 
to be effective at detecting significant fibrosis and 
cirrhosis to at least some degree. However, recent 
evidence suggests that various combinations of these 
techniques may be helpful both as an alternative to 
liver biopsy, which has significant associated morbidity 
and mortality, and as a cost-effective tool to identify 
sub-clinical disease.
SUMMARY OF KEY POINTS
Chronic liver disease develops over many years 
following ongoing injury and is characterised by 
progressive scarring caused by fibrosis. Hepatic 
steatosis is increasingly being recognised as an 
important factor in a number of chronic liver diseases 
and occurs when the rate of synthesis or import of 
fatty acids by hepatocytes exceeds the rate of export 
or catabolism. Serum markers measure both direct 
and indirect markers of liver fibrosis although these 
have had limited success as individual markers of 
fibrosis. Imaging modalities to assess liver disease 
can be used to quantify morphological changes, 
portal hypertension, vascular remodelling and 
liver stiffness associated with increasing fibrosis. 
The most widely used and successful of these are 
transient elastography and acoustic radiation force 
impulse imaging although MRI techniques are very 
promising. Combination techniques involving transient 
elastography and various serum markers can provide 
good diagnostic accuracy and a reduced need for liver 
biopsy in patients with significant fibrosis. This has also 
proved successful as a screening tool in for patients in 
a community setting.
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